[go: up one dir, main page]

EA200701166A1 - Альфа-тимозиновые пептиды в качестве адъювантов противораковых вакцин - Google Patents

Альфа-тимозиновые пептиды в качестве адъювантов противораковых вакцин

Info

Publication number
EA200701166A1
EA200701166A1 EA200701166A EA200701166A EA200701166A1 EA 200701166 A1 EA200701166 A1 EA 200701166A1 EA 200701166 A EA200701166 A EA 200701166A EA 200701166 A EA200701166 A EA 200701166A EA 200701166 A1 EA200701166 A1 EA 200701166A1
Authority
EA
Eurasian Patent Office
Prior art keywords
alpha
timozyny
antjovants
peptides
cancer vaccines
Prior art date
Application number
EA200701166A
Other languages
English (en)
Other versions
EA015510B1 (ru
Inventor
Густаво Антонио Мовиглия
Алфред Р. Рудолф
Original Assignee
Сциклон Фармасьютикалс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сциклон Фармасьютикалс, Инк. filed Critical Сциклон Фармасьютикалс, Инк.
Publication of EA200701166A1 publication Critical patent/EA200701166A1/ru
Publication of EA015510B1 publication Critical patent/EA015510B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

В заявке описаны фармацевтическая комбинация и способ повышения эффективности противораковой вакцины у субъекта, применение индуцирующей иммунный ответ противораковой вакцины, способной вызывать ответ иммунной системы у субъекта, и количество альфа-тимозинового пептида, повышающего эффективность вакцины, повышающее ответ иммунной системы у субъекта, причем противораковая вакцина и альфа-тимозиновый пептид могут вводиться в организм по отдельности или совместно.
EA200701166A 2004-12-06 2005-12-06 Способ увеличения количества мононуклеарных клеток у субъекта, страдающего раком, и используемая для этого фармацевтическая комбинация EA015510B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63317504P 2004-12-06 2004-12-06
PCT/US2005/043985 WO2006062917A2 (en) 2004-12-06 2005-12-06 Alpha thymosin peptides as cancer vaccine adjuvants

Publications (2)

Publication Number Publication Date
EA200701166A1 true EA200701166A1 (ru) 2008-02-28
EA015510B1 EA015510B1 (ru) 2011-08-30

Family

ID=36578462

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200701166A EA015510B1 (ru) 2004-12-06 2005-12-06 Способ увеличения количества мононуклеарных клеток у субъекта, страдающего раком, и используемая для этого фармацевтическая комбинация

Country Status (15)

Country Link
US (1) US20100092499A1 (ru)
EP (1) EP1835931A4 (ru)
JP (1) JP2008523067A (ru)
KR (1) KR20070086663A (ru)
CN (1) CN101072582B (ru)
AU (1) AU2005314271B2 (ru)
BR (1) BRPI0518571A2 (ru)
CA (1) CA2588685A1 (ru)
EA (1) EA015510B1 (ru)
IL (1) IL183264A (ru)
MX (1) MX2007006717A (ru)
NO (1) NO20072705L (ru)
NZ (1) NZ555571A (ru)
UA (1) UA90493C2 (ru)
WO (1) WO2006062917A2 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100317583A1 (en) * 2007-12-14 2010-12-16 Sciclone Pharmaceuticals, Inc. Treatment of melanoma with alpha thymosin peptides in combination with an antineoplastic heat shock apoptosis activator (hsaa)
US8716012B2 (en) 2009-05-08 2014-05-06 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as vaccine enhancers
US20140213506A1 (en) * 2011-02-09 2014-07-31 Cynthia W. TUTHILL Thymosin alpha peptide for preventing, reducing the severity of, and treating infection
CN104136040B (zh) * 2012-01-20 2021-05-25 费尔南多·托姆·克罗伊茨 自体癌细胞疫苗
WO2013134666A1 (en) * 2012-03-08 2013-09-12 Sciclone Pharmaceuticals, Inc. Use of thymosin alpha for treatment of purulent rhinosinusitis
SG11201702558VA (en) * 2014-10-21 2017-05-30 Sciclone Pharmaceuticals Inc Treatment of cancer with immune stimulators
CN107281476B (zh) * 2017-04-06 2020-11-24 中国医科大学 一种抗原肽RL-佐剂CpGODN7909偶联物及其制备方法和应用
RU2645957C1 (ru) * 2017-04-10 2018-02-28 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ лечения лучевых повреждений мочевого пузыря
RU2663468C1 (ru) * 2017-09-25 2018-08-06 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ лечения местно-распространенного нерезектабельного рака поджелудочной железы

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US653758A (en) * 1900-03-20 1900-07-17 Austin Gale Hay-stacking device.
DE2604845A1 (de) * 1976-02-07 1977-08-18 Knoll Ag Neue piperazinderivate
JPH0420624A (ja) * 1990-02-06 1992-01-24 Kanji Yokoe 勾配側溝施工法及び当該工法に使用する可変側溝
US6537585B1 (en) * 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
CA2380873A1 (en) * 1999-06-30 2001-01-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
DE60224435T2 (de) * 2001-10-26 2009-01-02 Rhode Island Hospital Thymosin-augmentation bei genetischer immunisierung
CA2498591A1 (en) * 2001-10-26 2003-05-01 Immuno-Rx, Inc. Immunotherapy for reversing immune suppression
JP2005537246A (ja) * 2002-06-28 2005-12-08 サイクローン・ファーマシューティカルズ・インコーポレイテッド サイマルファシンを用いて腫瘍抗原発現をアップレギュレートする方法
ATE467422T1 (de) * 2003-03-28 2010-05-15 Sciclone Pharmaceuticals Inc Behandlung von aspergillus-infektionen mit thymosin alpha 1
ES2428358T3 (es) * 2003-10-17 2013-11-07 Novo Nordisk A/S Terapia de combinación
US8716012B2 (en) * 2009-05-08 2014-05-06 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as vaccine enhancers

Also Published As

Publication number Publication date
CN101072582B (zh) 2012-06-27
AU2005314271A1 (en) 2006-06-15
UA90493C2 (ru) 2010-05-11
NO20072705L (no) 2007-09-05
CA2588685A1 (en) 2006-06-15
BRPI0518571A2 (pt) 2008-11-25
MX2007006717A (es) 2007-08-06
IL183264A (en) 2010-12-30
JP2008523067A (ja) 2008-07-03
WO2006062917A3 (en) 2006-11-16
US20100092499A1 (en) 2010-04-15
NZ555571A (en) 2009-02-28
EP1835931A4 (en) 2008-12-17
KR20070086663A (ko) 2007-08-27
AU2005314271B2 (en) 2011-06-16
CN101072582A (zh) 2007-11-14
EA015510B1 (ru) 2011-08-30
EP1835931A2 (en) 2007-09-26
WO2006062917A2 (en) 2006-06-15
IL183264A0 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
WO2012027379A3 (en) Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
ES2485316T3 (es) Usos inmunológicos de compuestos inmunomoduladores para vacunas y terapia anti-enfermedades infecciosas
MX2009001412A (es) Vacunas de matriz de proteinas y metodos de hacer y administrar tales vacunas.
EA201170493A1 (ru) Микроорганизмы и вакцины, зависимые от репликации неприродных аминокислот
WO2010066418A8 (de) Verwendung von flt3-ligand zur verstärkung von immunreaktionen bei rna-immunisierung
EA201892671A1 (ru) Пегилированный свиной интерферон и способы его применения
WO2006081007A3 (en) Use of flagellin in tumor immunotherapy
WO2007103048A3 (en) Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
WO2008098212A3 (en) Extended release formulations of glucagon and other peptides and proteins
EP4272750A3 (en) Protein antigens that provide protection against pneumococcal colonization and/or disease
WO2008054535A3 (en) Novel influenza m2 vaccines
EP4226938A3 (en) Coronavirus vaccine
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
NO20072705L (no) Alfa-tymosinpeptider som cancervaksineadjuvanser
EA201171032A1 (ru) Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами
WO2005007673A3 (en) Immunogenic peptides
MD20100029A (ro) Herpesvirus recombinant al crapului de koi (KHV) sau Cyprinid herpesvirus 3 (CyHV-3) si vaccin pentru prevenirea bolii cauzate de KHV/CyHV-3 la Cyprinus carpio carpio sau Cyprinus carpio koi
CL2009001195A1 (es) Adyuvante inmune que comprende un inhibidor de iap capaz de modular la actividad inmune; composicion farmaceutica y vacuna que lo comprenden; metodo para mejorar una respuesta inmune de un individuo; metodo para tratar un cancer en un individuo; metodo para tratar infeccion; metodo para tratar trastornos autoinmune.
WO2006115843A3 (en) Nipah virus vaccines
EP3858369A4 (en) Cancer therapy where oncolytic vaccinia virus and immune checkpoint inhibitor are used in combination, and pharmaceutical composition and combination drug used therein
DE60331725D1 (de) Therapeutische mittel als antikrebs impfstoffadjuvantien und deren therapeutische verfahren
GB0118532D0 (en) Materials and methods relating to improved vaccination strategies
WO2010129947A3 (en) Alpha thymosin peptides as vaccine enhancers
WO2003093298A3 (en) Immunogenic peptides
TNSN08184A1 (en) Chimeric antigens and vaccines

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU